Research satisfaction among participants in a preclinical Alzheimer's disease trial

IF 12.8 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2026-09-23 DOI:10.1002/alz.71852

Marina Ritchie, Kedir Hussen, Oliver Langford, Michael C. Donohue, Mary Sano, Joshua D. Grill, Paul Aisen, Reisa Sperling, Rema Raman

{"title":"Research satisfaction among participants in a preclinical Alzheimer's disease trial","authors":"Marina Ritchie, Kedir Hussen, Oliver Langford, Michael C. Donohue, Mary Sano, Joshua D. Grill, Paul Aisen, Reisa Sperling, Rema Raman","doi":"10.1002/alz.71852","DOIUrl":null,"url":null,"abstract":"INTRODUCTION Empirical data capturing participants’ experiences in preclinical Alzheimer's disease (AD) trials are limited. We examined participant responses on a Research Satisfaction Survey (RSS) from the Anti‐Amyloid Treatment in Asymptomatic AD Study. METHODS Participants completed the RSS at week 0, 48, 108, 168, and 240. We examined potential differences in responses by baseline participant characteristics and trial completion status. RESULTS RSS scores were high, with > 90% of participants responding positively to all satisfaction items. Across timepoints, altruistic motivations were most frequently affirmed, while study design elements were most frequently disfavored. Affirmation of social motivations increased over time. Participants who responded “not satisfied” at baseline to repeating their decision to enroll had higher odds of study discontinuation than those who responded “satisfied” (1.99; 95% confidence interval [CI]:1.24, 3.19). DISCUSSION An RSS captures participant experiences in a preclinical AD trial, can guide decisions on study design features, and may identify those at risk for loss to follow‐up.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"51 1","pages":""},"PeriodicalIF":12.8000,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.71852","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION Empirical data capturing participants’ experiences in preclinical Alzheimer's disease (AD) trials are limited. We examined participant responses on a Research Satisfaction Survey (RSS) from the Anti‐Amyloid Treatment in Asymptomatic AD Study. METHODS Participants completed the RSS at week 0, 48, 108, 168, and 240. We examined potential differences in responses by baseline participant characteristics and trial completion status. RESULTS RSS scores were high, with > 90% of participants responding positively to all satisfaction items. Across timepoints, altruistic motivations were most frequently affirmed, while study design elements were most frequently disfavored. Affirmation of social motivations increased over time. Participants who responded “not satisfied” at baseline to repeating their decision to enroll had higher odds of study discontinuation than those who responded “satisfied” (1.99; 95% confidence interval [CI]:1.24, 3.19). DISCUSSION An RSS captures participant experiences in a preclinical AD trial, can guide decisions on study design features, and may identify those at risk for loss to follow‐up.

查看原文本刊更多论文

阿尔茨海默病临床前试验参与者的研究满意度

临床前阿尔茨海默病（AD）试验中获取参与者经验的经验数据是有限的。我们检查了无症状AD抗淀粉样蛋白治疗研究中参与者的研究满意度调查（RSS）。方法参与者在第0、48、108、168和240周完成RSS。我们通过基线参与者特征和试验完成状态检查了反应的潜在差异。结果：受试者的RSS评分较高，90%的受试者对所有满意项目都有积极的反应。在各个时间点上，利他动机最常被肯定，而研究设计元素最常被反对。随着时间的推移，对社交动机的肯定也在增加。在基线时回答“不满意”的参与者重复其入组决定的几率高于回答“满意”的参与者（1.99；95%可信区间[CI]:1.24, 3.19）。RSS捕获临床前AD试验参与者的经验，可以指导研究设计特征的决策，并可以识别那些有失去随访风险的人。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.